Tomivosertib, also known as eFT-508, is a potent, highly selective and orally bioavailable MNK1 and MNK2 inhibitor that is currently under investigation in Phase 1/2 clinical trials for the treatment of patients with advanced solid tumors and lymphomas . Each of eFFECTOR's product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion.
Clinical Trials and Studies at USC This work was supported by the National Nature Science Foundation of China (grants 81872462 and 81972772) and the Clinical Trial Supporting Foundation of Tianjin Medical University Cancer Institute & Hospital (grant C1707). A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First Line . Background. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: interim results of a clinical trial . We thank Jiangsu HengRui Medicine Co., China, for kindly providing the anti-PD-1 antibody camrelizumab.
An Open-label Study Examining the Effect of Tomivosertib (eFT508) in ... KICKSTART: A study of Tomivosertib | eFFECTOR Inhibitory effects of Tomivosertib in acute myeloid leukemia Clinical Trial on Breast Cancer: tomivosertib, paclitaxel - ICH GCP This drug entry is a stub and has not been fully annotated. Our trial will determine if the potent MNK inhibitor, tomivosertib, controls tumor growth either directly or by enhancing anti-tumor immunity.
eFFECTOR Therapeutics Reports Third Quarter 2021 ... - Green Stock News The trial will enroll up to 45 patients with an Eastern Cooperative Oncology Group (ECOG) performance . mi. including clinical trial and manufacturing delays; our ability to access the LPC facility is subject to certain conditions; our . Tomivosertib (eFT-508) For research use only. that together control tumor growth, survival and immune evasion.
eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 ... - PM360 Reversal of peripheral nerve injury-induced neuropathic pain and ... The time until each animal fell was recorded for each trial. The company's research program currently has two novel drug candidates undergoing clinical trials.
2021-11-08 | NDAQ:EFTR | Press Release - stockhouse eFFECTOR Therapeutics Doses First Patient in Phase 2b ... - TMCNet Tomivosertib (formerly eFT 508) is a highly selective, orally available, small molecule inhibitor of MNK1 and MNK2, . . In addition, Dr. Patel will serve as a consultant to eFFECTOR through September 30, 2022. we may use our capital resources sooner than expected and they may be insufficient to allow clinical trial readouts; regulatory developments in the United States and foreign countries . Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance. This study will evaluate the safety and antitumor activity of tomivosertib versus placebo in subjects .
eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and ... Previously received investigational product in a clinical trial within 30 days or within 5 elimination half-lives (whichever is longer) prior to the start of Tomivosertib (eFT-508), or is planning to take part in another clinical trial while participating in this study; Tomivosertib (eFT508): eFFECTOR's wholly-owned, highly selective MNK inhibitor designed to enhance anti-tumor immune activity by stimulating activation, delaying exhaustion, and prolonging the memory of T cells. This is a multicenter, open-label trial to evaluate the safety, pharmacodynamics (PD), pharmacokinetics (PK), and efficacy of tomivosertib in combination with paclitaxel in patients with advanced breast cancer (ABC) of any subtype. The trial (NCT03690141), currently recruiting participants, will evaluate the safety, tolerability and antitumor activity of .
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year Kickstart is a double-blind, randomized, multi-center Phase 2b clinical trial. Tomivosertib (10 mg/kg i.p ~50 μL) or vehicle was then injected, and 1 h later all mice were tested twice more, and their scores were averaged.
2 'Strong Buy' Stocks That Could Be Bought Out, According to Credit ... Status: Enrolling Updated: 12/31/1969 Anne Arundel Medical Center. Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. eFFECTOR is supplying .
Clinical Trial: NCT04261218 - My Cancer Genome Previously received investigational product in a clinical trial within 30 days or within 5 elimination half-lives (whichever is longer) prior to the start of Tomivosertib (eFT-508), or is planning to take part in another clinical trial while participating in this study; "2021 was a momentous year for eFFECTOR, as we advanced both our clinical stage assets, tomivosertib and zotatifin, into Phase 2 trials and raised additional capital with our debut as a public . NCT04261218. The randomized trial will treat patients who have non-small cell lung cancer (NSCLC) with a combination of tomivosertib and Keytruda (pembrolizumab). A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With .
Tomivosertib Completed Phase 2 Trials for Castration ... - DrugBank eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity Generic Name. Zotatifin Update
eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to ... 01 Apr 2021 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT04622007) Tomivosertib (formerly eFT 508) is a highly selective, orally available, small molecule inhibitor of MNK1 and MNK2, .
eFFECTOR Therapeutics Announces Transition in Clinical ... - BioSpace SAN DIEGO and REDWOOD CITY, Calif., June 05, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today reported positive interim results of the company's ongoing Phase 1/2 clinical trial of eIF4A inhibitor . SAN DIEGO, July 27, 2018 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in a Phase 2 clinical trial of eFT508 (tomivosertib), the company's oral, small molecule inhibitor of MNK1/2, added on to patients already receiving an FDA-approved anti-PD-1 or anti . . Enrollment in SU2C Breast Cancer Trial continues: Tomivosertib is being evaluated in an ongoing Phase 2a clinical trial in patients with metastatic breast cancer in combination with paclitaxel chemotherapy in a study led by Professor Nahum Sonenberg Ph.D., Gilman Cheney Chair in Biochemistry at McGill University.
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that ... Tomivosertib - Effector Therapeutics - AdisInsight Tomivosertib - Effector Therapeutics - AdisInsight This trial; Search. SAN DIEGO and REDWOOD CITY, Calif., June 05, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today reported positive interim results of the company's ongoing Phase 1/2 clinical trial of eIF4A inhibitor zotatifin in patients with solid tumors that showed . SAN DIEGO, CA, USA I July 27, 2018 I eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in a Phase 2 clinical trial of eFT508 (tomivosertib), the company's oral, small molecule inhibitor of MNK1/2, added on to patients already receiving an FDA-approved anti-PD-1 .
Mnk inhibitors: a patent review - PubMed Tomivosertib (eFT508) is a novel small-molecule inhibitor of MNK that delays T cell exhaustion/dysfunction and is being developed in combination with pembrolizumab in 1L NSCLC patients with PD-L1 ≥ 1%.
Solid Tumors (eFT508-0010) | Spartanburg Regional Principal Investigator It is scheduled to be annotated soon. An upcoming Phase 2 trial will evaluate a combination of the immunotherapies Keytruda (pembrolizumab) and tomivosertib (eFT508) as a treatment for triple-negative breast cancer patients whose disease has spread to other regions, or metastasized.. As part of a new collaboration between eFFECTOR Therapeutics and Merck (known as MSD outside the U.S. and Canada), the trial will test the .
Pipeline | eFFECTOR eFFECTOR Therapeutics Provides Pipeline and Business Updates eFFECTOR's lead product candidate, tomivosertib, is a MNK . Tomivosertib (eFT508): eFFECTOR's wholly-owned, highly selective MNK inhibitor designed to enhance anti-tumor activity by stimulating activation, .
Medicine Demonstrates Immunological Effects of Tomivosertib from . Protocol No. Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. Tomivosertib is now in phase 2 clinical trials. A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L) .
Tyler Research and Clinical Trials | Texas Oncology A Randomized, Double-Blind, Placebo-Controlled Trial ... - New York It potentially results in decreased tumor cell proliferation and tumor growth. Multiple Myeloma. If results from the KICKSTART trial are clinically . Enrollment in SU2C Breast Cancer Trial continues: Tomivosertib is being evaluated in an ongoing Phase 2a clinical trial in patients with metastatic breast cancer in combination with paclitaxel . Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) .
eFFECTOR Therapeutics Reports First Quarter 2022 Financial ... - BioSpace Identification. DB15219.
Tomivosertib (eFT508) | MNK1/2 Inhibitor | MedChemExpress Lung Cancer Studies . "The TNBC trial will expand the current tomivosertib Phase 2 clinical trial program, allowing eFFECTOR to explore a combination with KEYTRUDA for an indication in which neither drug is yet approved," said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR."Based on preclinical studies showing tomivosertib has substantial immunomodulatory activity and synergizes with . .
A Randomized, Double-Blind, Placebo-Controlled Trial ... - New York DrugBank Accession Number. This is an open-label, Phase 1-2, first-in-human study for CX-2029 in subjects with metastatic or locally advanced unresectable solid tumors or Diffuse large B-cell lymphoma (DLBCL) without approved life-prolonging . A clinical trial for an investigational respiratory syncytial virus (RSV) vaccine combined with an approved flu vaccine for older adults. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines.
Phase 2 Breast Cancer Trial to Test Keytruda, Tomivosertib Combination